Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC161-DP0293
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Administration
- Topical
01
Overview
DC161-DP0293 is an experimental oromucosal spray formulation developed by Pierre Fabre as a saliva substitute. It is intended to relieve drug-induced xerostomia (dry mouth) associated with hyposialia, a condition characterized by reduced salivation often caused by chronic medication use. As a topical medical device, DC161-DP0293 acts as a mechanical lubricant to hydrate the oral cavity, mimicking the properties of natural saliva without targeting specific biological receptors. It was evaluated in a Phase 1 clinical trial (NCT02005328) to assess its efficacy and safety compared to other DC161 formulations and a reference product.
- Other names
- DC161 oral sprayDC-161 oral sprayDC 161 oral spray
Beyond the preview
Go deeper on DC161-DP0293.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC161-DP0293.